Baird Upgrades Qiagen to Outperform, Lowers Price Target to $43

Benzinga Newsdesk www.benzinga.com Negative 86.3%

Neg 86.3% Neu 0% Pos 0%

Baird analyst Catherine Schulte upgrades Qiagen (NYSE:QGEN) from Neutral to Outperform and lowers the price target from $53 to $43.